NVS vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 23, 2026

NVS

70.7
AI Score
VS
NVS Wins

GSK

52.0
AI Score

Investment Advisor Scores

NVS

71score
Recommendation
HOLD

GSK

52score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric NVS GSK Winner
Forward P/E 14.5349 9.8328 GSK
PEG Ratio 3.3032 6.1456 NVS
Revenue Growth 0.8% 5.3% GSK
Earnings Growth -17.0% -69.5% NVS
Tradestie Score 70.7/100 52.0/100 NVS
Profit Margin 22.5% 14.5% NVS
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

NVS 1M: -13.2% · 3M: -9.3% GSK 1M: -6.8% · 3M: -11.4%

Current Technical Phase

NVS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 40

RSI (14): 40.5 · Price: $141.00

GSK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.1%), weak momentum, RSI 34

RSI (14): 33.8 · Price: $47.03

Fundamentals Snapshot

Metric NVS GSK
Market Cap — —
Forward P/E 14.3 9.4
Trailing P/E 21.3 15.5
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.7% 0.7%
Operating Margin 0.3% 0.3%
EPS 6.62 3.05
Dividend Yield 0.03% 0.04%

Frequently Asked Questions

Based on our detailed analysis, NVS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.